The facility is expected to allow Singapore’s science and technology sector to accelerate the research, development and manufacturing of critical medicines and vaccines
Thermo Fisher Scientific has opened a new sterile drug facility in Singapore to expand sterile manufacturing and research capabilities in the Asia-Pacific region.
The new facility is expected to enable customers to deliver new medicines and vaccines in the Asia-Pacific market.
The current Good Manufacturing Practises (cGMP) facility was built with assistance from the Singapore Economic Development Board (EDB), in line with the government’s investment in preparedness for upcoming health emergencies.
Thermo Fisher Scientific said the plant will offer rapid vaccine fill-finish capabilities in addition to its end-to-end pharmaceutical development and manufacturing services. It houses a high-speed, fully automated aseptic fill-finish line for small and large molecules.
Thermo Fisher Scientific executive vice president and chief operating officer Michel Lagarde said: “We are committed to serving as a reliable partner to the Asia-Pacific region and the world.
“This new site is an important extension of Thermo Fisher’s robust sterile fill-finish global network. With this expansion, we are strategically prepared, more than ever, to respond to our customers’ needs by supporting the accelerated delivery of critical vaccines and medicines to patients.”
According to the company, the strategic investment in Singapore complements new research capabilities at its Customer Experience Centre and Bioprocess Design Centre.
It will also support two other operational lab facilities that have the latest bioprocessing, life science, and analytical technologies.
The Customer Experience Centre offers a wide range of products for Asia, including more than 250 products in a variety of sectors such as molecular biology, genetic analysis and sequencing, chromatography and mass spectrometry, and cell treatment.
The Bioprocess Design Centre offers expertise in bioprocessing and process scale-up to assist scientists and engineers with education and specialised services to hasten the development of new processes.
Thermo Fisher said that these sites will enable customers to accelerate their research and develop and market new medicines and vaccines in the Asia-Pacific market.